Cargando…
Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis
Non-alcoholic steatohepatitis (NASH) is defined as hepatic steatosis, inflammation, and hepatocyte injury with or without fibrosis. It has emerged as the second leading indication for liver transplantation with a rising death rate in the non-transplantable population. While there are many drugs in e...
Autores principales: | Suri, Jaspreet, Borja, Sebastian, Lim, Joseph K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516677/ https://www.ncbi.nlm.nih.gov/pubmed/36188726 http://dx.doi.org/10.3748/wjg.v28.i35.5129 |
Ejemplares similares
-
Mechanisms of ductular reaction in non-alcoholic steatohepatitis
por: Chen, Yue, et al.
Publicado: (2022) -
Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
por: Tovo, Cristiane Valle, et al.
Publicado: (2023) -
Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?
por: Cao, Ying, et al.
Publicado: (2020) -
Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
por: Ocker, Matthias
Publicado: (2020) -
Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
por: Chackelevicius, Carla Melisa, et al.
Publicado: (2016)